Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055692 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer
A Phase 2 study of Localized Unresectable Adult Primary Liver Cancer and Recurrent Adult Primary Liver Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT00055692: Completed Phase 2 study of Localized Unresectable Adult Primary Liver Cancer and Recurrent Adult Primary Liver Cancer, sponsored by National Cancer Institute (NCI).
NCT00055692 is a Phase 2 study of Localized Unresectable Adult Primary Liver Cancer and Recurrent Adult Primary Liver Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 46 participants, above the 20-participant average among 5 other Localized Unresectable Adult Primary Liver Cancer trials with a reported enrollment target (130% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00055692, a Phase 2 study of Localized Unresectable Adult Primary Liver Cancer and Recurrent Adult Primary Liver Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is to see if bevacizumab works in treating patients who have unresectable nonmetastatic liver cancer that has not spread to the main portal vein. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them.
Conditions Studied
Interventions
- BIOLOGICAL bevacizumab
Study Locations (1)
New York
- Montefiore Medical Center - Moses Campus - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2003-02 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
What the finished NCT00055692 record still lists
NCT00055692 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, above the 20-participant average among 5 other Localized Unresectable Adult Primary Liver Cancer trials with a reported enrollment target (130% higher).
The record links to 3 conditions, with Localized Unresectable Adult Primary Liver Cancer appearing as the primary indexed condition, and to 1 intervention - of which bevacizumab is the first listed.
NCT00055692 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00055692 about?
NCT00055692 is a clinical study titled "Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer". This phase II trial is to see if bevacizumab works in treating patients who have unresectable nonmetastatic liver cancer that has not spread to the main portal vein. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow ...
What is the current status of trial NCT00055692?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2003-02. Estimated completion is 2009-12.
What conditions does trial NCT00055692 study?
This clinical trial studies the following conditions: Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Adult Primary Hepatocellular Carcinoma.
What interventions are being tested in trial NCT00055692?
The interventions under investigation include: bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00055692?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00055692 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Localized Unresectable Adult Primary Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TSR-022 (anti-TIM-3 Antibody) and TSR-042 (anti-PD-1 Antibody) in Patients with Liver Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
COMPLETED · Phase 2
-
Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT
ACTIVE NOT RECRUITING
-
Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant
COMPLETED · Phase 1
-
Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia